| 115.24 -1.06 (-0.91%) | 05-15 16:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 140.28 | 1-year : | 163.85 |
| Resists | First : | 120.11 | Second : | 140.28 |
| Pivot price | 116.84 |
|||
| Supports | First : | 114.32 | Second : | 110.75 |
| MAs | MA(5) : | 117.15 |
MA(20) : | 115.95 |
| MA(100) : | 124.21 |
MA(250) : | 132.1 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 45.6 |
D(3) : | 57.8 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 170 | Low : | 110.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PKI ] has closed above bottom band by 39.8%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 117.38 - 118.08 | 118.08 - 118.76 |
| Low: | 113.68 - 114.52 | 114.52 - 115.32 |
| Close: | 115.04 - 116.27 | 116.27 - 117.45 |
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Fri, 19 May 2023
PerkinElmer Completes Transformation to Become Revvity - Yahoo Finance
Tue, 14 Mar 2023
PerkinElmer (PKI) Completes Divestment, New Business Name in Q2 - Nasdaq
Mon, 13 Mar 2023
PerkinElmer Completes Divestiture of its Applied, Food and Enterprise Services Businesses - Business Wire
Mon, 01 Aug 2022
PerkinElmer divests three business units in $2.45 bln deal - Reuters
Wed, 22 Sep 2021
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend - News-Medical
Mon, 26 Jul 2021
PerkinElmer (PKI) Buys BioLegend for $5.25 Billion in Cash, Stock - Bloomberg.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 125 (M) |
| Shares Float | 116 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 86.2 (%) |
| Shares Short | 3,530 (K) |
| Shares Short P.Month | 3,320 (K) |
| EPS | 2.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 58.45 |
| Profit Margin | 17.1 % |
| Operating Margin | 25.9 % |
| Return on Assets (ttm) | 3.6 % |
| Return on Equity (ttm) | 7 % |
| Qtrly Rev. Growth | -27.9 % |
| Gross Profit (p.s.) | 16.26 |
| Sales Per Share | 26.38 |
| EBITDA (p.s.) | 10.28 |
| Qtrly Earnings Growth | -32.5 % |
| Operating Cash Flow | 680 (M) |
| Levered Free Cash Flow | -262 (M) |
| PE Ratio | 41.84 |
| PEG Ratio | -8.3 |
| Price to Book value | 1.98 |
| Price to Sales | 4.4 |
| Price to Cash Flow | 21.46 |
| Dividend | 0.07 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|